← Human Trials & Peer-Reviewed Studies
Effect of a 'tobacco-free nicotine' claim on intentions and perceptions of Puff Bar e-cigarette use among non-tobacco-using young adults.
Plain-language guide to PMID 34697090 (2023): randomized controlled trial of Therapeutic nicotine (patch, non-peptide).
Key Facts
- PMID
- 34697090
- Journal
- Tobacco control
- Year
- 2023
- Study type
- Randomized Controlled Trial
- Authors
- Chen-Sankey J et al. (4 authors)
- DOI
- 10.1136/tobaccocontrol-2021-056957
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Therapeutic nicotine (patch, non-peptide).
Multivariable regressions were used to assess the associations between experimental conditions and Puff Bar use intentions, harm perceptions, use expectancies and perceived relative use of Puff Bar versus other e-cigarettes, controlling for participant characteristics.
Why It Was Studied
Puff Bar disposable e-cigarettes are now marketed with a 'tobacco-free nicotine' claim.
The researchers assessed the effect of this claim on non-tobacco-using young adults' perceptions of and intentions of using Puff Bar.
Who Took Part
PubMed indexes the participants as young adults.
The researchers conducted an online randomised between-subjects experiment among non-tobacco-using young adults (ages 18-29 years; n=1822).
Participants viewed depictions of Puff Bar e-cigarettes with the claim that the product contains 'tobacco-free nicotine' (experimental group; n=909) or simply 'nicotine' (control group; n=913).
How the Study Was Run
The design is described as randomized.
Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.
What Was Measured
The researchers assessed the effect of this claim on non-tobacco-using young adults' perceptions of and intentions of using Puff Bar.
Topics PubMed links to this paper include Electronic Nicotine Delivery Systems, Intention, Nicotine, Smoking, Tobacco Products and Vaping.
Author keywords: advertising and promotion and electronic nicotine delivery devices.
What This Means in Plain Language
The paper is a randomized study of Therapeutic nicotine (patch, non-peptide).
The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2023 (Tobacco control), a journal based in England.
More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.
Our Notes on the Compound
Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.